AI drug discovery firm BenevolentAI to merge with Odyssey in €1.5bn deal
BenevolentAI, a clinical-stage artificial intelligence (AI) drug discovery company, has agreed to merge with blank cheque company Odyssey Acquisition, in a deal that values the former at €1.1bn.